BIO-TECHNE earnings release, May 6, 2026
Bio-Techne Releases Third Quarter Fiscal 2026 Results
Minneapolis/May 6, 2026/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026.
Third Quarter FY2026 Highlights
● Reported and organic revenue declined 2% to $311.4M, negatively impacted by prior-year GMP fast-track orders and timing of large Commercial Supply shipments
● GAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56
● Large pharma delivered the sixth consecutive quarter of double-digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low-single-digit growth
● Growth vectors performed well, with mid-single-digit growth in Proteomic Analysis instruments, mid-teens growth in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast-track customers
“The Bio-Techne team delivered solid execution amid a mixed end-market environment,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “Large pharma again led results with the sixth consecutive quarter of double-digit growth, supported by momentum in Asia and stabilizing U.S. academic demand. While biotech funding remains healthy, it has not yet translated into broad-based demand across our portfolio.”
Kelderman continued, “We are encouraged by early indicators pointing to a more constructive outlook as funding activity and customer purchasing begin to realign. Our portfolio is organized to support durable, high-value applications across the scientific journey, from biological discovery and translational insight to therapeutic development, manufacturing, and precision diagnostics. Together with our strong operating discipline and financial flexibility, Bio-Techne remains well positioned to deliver attractive long-term value for our stakeholders.”
Conference Call
Bio-Techne will host an earnings conference call today, May 6, 2026, at 8:00 a.m. CDT. To listen, please dial 1-800-343-4136 or 1-203-518-9843 (for international callers), and reference conference ID TECHQ3. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11161556. The replay will be available from 11:00 a.m. CDT on Wednesday, May 6, 2026, until 11:00 p.m. CDT on Saturday, June 6, 2026.
Third Quarter Fiscal 2026
Revenue
Net sales for the third quarter decreased 2% to $311.4 million. Organic revenue decreased 2% compared to the prior year, with foreign currency exchange having a favorable impact of 2%, and non-recurring prior year revenue from a business held-for-sale having an unfavorable impact of 2%.
GAAP Earnings Results
GAAP EPS was $0.32 per diluted share versus $0.14 in the same quarter last year. GAAP operating income for the third quarter of fiscal 2026 increased 95% to
$75.5 million compared to $38.7 million in the third quarter of fiscal 2025. GAAP operating margin was 24.2% compared to 12.2% in the third quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by ongoing profitability initiatives, the Exosome Diagnostics divestiture, and a non-recurring arbitration payment in the prior year, partially offset by unfavorable product mix.
Non-GAAP Earnings Results
Adjusted EPS decreased to $0.53 per diluted share compared to $0.56 in the same quarter last year. Adjusted operating income decreased to $106.5 million in the third quarter of fiscal 2026 compared to $110.3 million in the third quarter of fiscal 2025. Adjusted operating margin was 34.2% for the third quarter of fiscal 2026 compared to 34.9% in the third quarter of fiscal 2025. Adjusted operating margin was unfavorably impacted by volume and product mix, partially offset by ongoing profitability initiatives and the Exosome Diagnostics divestiture.
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company’s business segments, as highlighted below.
Protein Sciences Segment
The Company’s Protein Sciences segment is one of the world’s leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The
Protein Sciences segment’s third quarter fiscal 2026 net sales were $226.2 million, a decrease of 1% from $227.7 million in the third quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment’s operating results for both periods presented. Organic revenue decreased 4% for the third quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 3%. The Protein Sciences segment’s operating margin decreased to 44.2% in the third quarter of fiscal 2026 compared to 45.6% in the third quarter of fiscal 2025. The segment’s operating margin decreased primarily due to unfavorable volume and product mix, partially offset by ongoing profitability initiatives.
Diagnostics and Spatial Biology Segment
The Company’s Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market.... (truncated)rd quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment’s fiscal 2026 operating results. Organic revenue growth was 3% for the third quarter of fiscal 2026, with foreign exchange having a favorable impact of 1%. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment’s operating margin increased to 12.1% in the third quarter of fiscal 2026 compared to 9.4% in the third quarter of fiscal 2025.
The segment’s operating margin was favorably impacted by the Exosome Diagnostics divestiture and ongoing profitability initiatives, partially offset by unfavorable product mix.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs approximately 3,100 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at
LinkedIn,
X, or
YouTube.
Forward Looking Statements:
Financial statements
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – March 31, – 2026 | Quarter Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | ||
|---|---|---|---|---|---|
| Net sales | 311,415 | 316,181 | 893,847 | 902,671 | |
| Cost of sales | 103,127 | 101,625 | 306,170 | 311,211 | |
| Gross margin | 208,288 | 214,556 | 587,677 | 591,460 | |
| Operating expenses: | Selling, general and administrative | 109,338 | 151,269 | 339,242 | 391,881 |
| Operating expenses: | Research and development | 23,455 | 24,579 | 70,821 | 73,464 |
| Operating expenses: | Total operating expenses | 132,793 | 175,848 | 410,063 | 465,345 |
| Operating expenses: | Operating income | 75,495 | 38,708 | 177,614 | 126,115 |
| Operating expenses: | Other income (expense) | -4,270 | -434 | -7,614 | -4,793 |
| Operating expenses: | Earnings before income taxes | 71,225 | 38,274 | 170,000 | 121,322 |
| Operating expenses: | Income taxes | 20,178 | 15,686 | 42,759 | 30,244 |
| Operating expenses: | Net earnings | 51,047 | 22,588 | 127,241 | 91,078 |
| Earnings per share: | Basic | 0.33 | 0.14 | 0.82 | 0.58 |
| Earnings per share: | Diluted | 0.32 | 0.14 | 0.81 | 0.57 |
| Weighted average common shares outstanding: | Basic | 156,327 | 157,372 | 155,893 | 158,117 |
| Weighted average common shares outstanding: | Diluted | 157,403 | 158,944 | 156,943 | 160,662 |
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – March 31, – 2026 | Quarter Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | ||
|---|---|---|---|---|---|
| Total consolidated net sales | 311,415 | 316,181 | 893,847 | 902,671 | |
| Business held-for-sale(1) | 5,439 | 4,152 | |||
| Revenue from recurring operations | 311,415 | 316,181 | 888,408 | 898,519 | |
| Gross margin - GAAP | 208,288 | 214,556 | 587,677 | 591,460 | |
| Gross margin percentage - GAAP | 66.9% | 67.9 | 65.7% | 65.5 | |
| Identified adjustments: | Costs recognized upon sale of acquired inventory | $— | 181 | $— | 554 |
| Identified adjustments: | Amortization of intangibles | 9,465 | 11,057 | 28,377 | 33,467 |
| Identified adjustments: | Stock-based compensation, inclusive of employer taxes | 400 | 378 | 1,252 | 1,010 |
| Identified adjustments: | Restructuring and restructuring-related costs | 1,152 | 364 | 4,756 | 7,953 |
| Identified adjustments: | Impact of business held-for-sale(1) | -2,581 | -147 | ||
| Identified adjustments: | Adjusted gross margin | 219,305 | 226,536 | 619,481 | 634,297 |
| Identified adjustments: | Adjusted gross margin percentage(2) | 70.4% | 71.6 | 69.7% | 70.6 |
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – March 31, – 2026 | Quarter Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | |
|---|---|---|---|---|
| Net earnings | 51,047 | 22,588 | 127,241 | 91,078 |
| Net interest expense (income) | 1,420 | 981 | 4,655 | 3,031 |
| Depreciation and amortization | 24,169 | 27,571 | 73,218 | 82,792 |
| Income taxes | 20,178 | 15,686 | 42,759 | 30,244 |
| EBITDA | 96,814 | 66,826 | 247,873 | 207,145 |
| Amortization of Wilson Wolf intangible assets | 2,490 | 2,491 | 7,469 | 7,471 |
| Acquisition related expenses and other | 1,042 | 5,290 | 6,789 | 9,477 |
| Certain litigation charges | 822 | 38,927 | 5,370 | 40,606 |
| Stock-based compensation, inclusive of employer taxes | 10,968 | 11,629 | 37,262 | 37,504 |
| Restructuring and restructuring-related costs | 2,952 | 716 | 14,201 | 15,027 |
| Investment (gain) loss and other non-operating (income) loss | 1,618 | 1,314 | ||
| Recovery of assets held-for-sale | -3,655 | -6,789 | -3,655 | |
| Impact of business held-for-sale(1) | 2,573 | 479 | ||
| Adjusted EBITDA | 116,706 | 122,224 | 316,062 | 314,054 |
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – March 31, – 2026 | Quarter Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | ||
|---|---|---|---|---|---|
| Net earnings before taxes - GAAP | 71,225 | 38,274 | 170,000 | 121,322 | |
| Identified adjustments: | Amortization of intangibles | 15,382 | 18,836 | 46,111 | 57,136 |
| Identified adjustments: | Amortization of Wilson Wolf intangible assets | 2,490 | 2,491 | 7,469 | 7,471 |
| Identified adjustments: | Acquisition related expenses and other | 1,042 | 5,290 | 6,789 | 9,477 |
| Identified adjustments: | Certain litigation charges | 822 | 38,927 | 5,370 | 40,606 |
| Identified adjustments: | Stock-based compensation, inclusive of employer taxes | 10,968 | 11,629 | 37,262 | 37,504 |
| Identified adjustments: | Restructuring and restructuring-related costs | 2,952 | 716 | 14,201 | 15,027 |
| Identified adjustments: | Investment (gain) loss and other non-operating (income) loss | 1,618 | 1,314 | ||
| Identified adjustments: | Recovery of assets held-for-sale | -3,655 | -6,789 | -3,655 | |
| Identified adjustments: | Impact of business held-for-sale(1) | 2,573 | 479 | ||
| Identified adjustments: | Net earnings before taxes - Adjusted | 106,499 | 112,508 | 284,300 | 285,367 |
| Identified adjustments: | Non-GAAP tax rate | 22.3% | 21.5% | 22.3% | 21.5% |
| Identified adjustments: | Non-GAAP tax expense | 23,749 | 24,190 | 63,399 | 61,385 |
| Identified adjustments: | Non-GAAP adjusted net earnings | 82,750 | 88,318 | 220,901 | 223,982 |
| Identified adjustments: | Earnings per share - diluted - Adjusted | 0.53 | 0.56 | 1.41 | 1.39 |
Income Statement
Quarter Ended — (Unaudited)
| Quarter Ended – March 31, – 2026 | Quarter Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | |
|---|---|---|---|---|
| Protein Sciences segment operating income | 99,999 | 103,910 | 262,327 | 271,564 |
| Diagnostics and Spatial Biology segment operating income | 10,319 | 8,423 | 27,629 | 15,940 |
| Segment operating income | 110,318 | 112,333 | 289,956 | 287,504 |
| Corporate general, selling, and administrative | -3,802 | -2,013 | -7,273 | -5,241 |
| Adjusted operating income | 106,516 | 110,320 | 282,683 | 282,263 |
| Amortization of intangibles | -15,382 | -18,836 | -46,111 | -57,136 |
| Acquisition related expenses and other | -897 | -5,159 | -6,341 | -9,051 |
Balance Sheet
(Unaudited)
| March 31, – 2026 | June 30, – 2025 | ||
|---|---|---|---|
| ASSETS | Cash and equivalents | 209,819 | 162,186 |
| ASSETS | Accounts receivable, net | 214,562 | 206,876 |
| ASSETS | Inventories | 201,175 | 189,446 |
| ASSETS | Current assets held-for-sale | 12,332 | |
| ASSETS | Other current assets | 62,494 | 37,460 |
| ASSETS | Total current assets | 688,050 | 608,300 |
| ASSETS | Property and equipment, net | 232,990 | 245,719 |
| ASSETS | Right of use assets | 68,316 | 73,399 |
| ASSETS | Goodwill and intangible assets, net | 1,296,874 | 1,346,534 |
| ASSETS | Other assets | 264,371 | 283,916 |
| ASSETS | Total assets | 2,550,601 | 2,557,868 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Accounts payable and accrued expenses | 95,601 | 116,765 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Contract liabilities | 38,433 | 32,571 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Income taxes payable | 2,971 | 10,770 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Operating lease liabilities - current | 14,181 | 14,098 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Other current liabilities | 2,092 | 1,645 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Total current liabilities | 153,278 | 175,849 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Deferred income taxes | 14,210 | 6,169 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Long-term debt obligations | 200,000 | 346,000 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Operating lease liabilities | 76,141 | 83,960 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Other long-term liabilities | 21,668 | 27,082 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Stockholders' equity | 2,085,304 | 1,918,808 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | Total liabilities and stockholders' equity | 2,550,601 | 2,557,868 |
Cash Flow
Nine Months Ended — (Unaudited)
| Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | ||
|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | Net earnings | 127,241 | 91,078 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Depreciation and amortization | 73,218 | 82,792 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Costs recognized on sale of acquired inventory | 554 | |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Deferred income taxes | 8,045 | -18,825 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Stock-based compensation expense | 36,135 | 36,283 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | (Gain) Loss on equity method investment | 335 | 169 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Asset impairment restructuring | 3,253 | 9,961 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Recovery of assets held-for-sale | -6,789 | -3,655 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Other operating activities | -44,781 | -9,002 |
| Adjustments to reconcile net earnings to net cash provided by operating activities | Net cash provided by (used in) operating activities | 196,657 | 189,355 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Proceeds from sale of available-for-sale investments | 1,085 | |
| CASH FLOWS FROM INVESTING ACTIVITIES | Additions to property and equipment | -20,370 | -26,116 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Distributions from Wilson Wolf | 4,620 | 2,653 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Investment in Spear Bio | -15,000 | |
| CASH FLOWS FROM INVESTING ACTIVITIES | Proceeds from sale of assets held-for-sale | 4,617 | 1,789 |
| CASH FLOWS FROM INVESTING ACTIVITIES | Net cash provided by (used in) investing activities | -11,133 | -35,589 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Cash dividends | -37,432 | -38,004 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Proceeds from stock option exercises | 58,193 | 45,513 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Long-term debt activity, net | -146,000 | 11,000 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Repurchases of common stock | -24 | -175,674 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Taxes paid on RSUs and net share settlements | -10,643 | -6,288 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Net cash provided by (used in) financing activities | -135,906 | -163,453 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Effect of exchange rate changes on cash and cash equivalents | -1,985 | -1,434 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Net increase (decrease) in cash and cash equivalents | 47,633 | -11,121 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Cash and cash equivalents at beginning of period | 162,186 | 151,791 |
| CASH FLOWS FROM FINANCING ACTIVITIES | Cash and cash equivalents at end of period | 209,819 | 140,670 |
Full release
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as “will,” “plan,” “continue,” “believe,” “outlook,” “expect,” and “predict.” These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company’s control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company’s customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning these risks, uncertainties, and other factors, see the section titled “Risk Factors” in the Company’s most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.
Non-GAAP Financial Measures:
The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include:
These non-GAAP measures should not be considered in isolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company’s use of these measures, are presented in the attached pages.
David.Clair@bio-techne.com
612-656-4416